Cybin CEO to Discuss Psychedelic Therapeutics and Regulatory Landscape in Upcoming Fireside Chat

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) has announced that its CEO, Doug Drysdale, will be a featured participant in a Water Tower Research Fireside Chat scheduled for May 29, 2025, at 11 a.m. ET. This event promises to shed light on several key aspects of Cybin's operations and the broader psychedelic therapeutics industry. Among the topics to be discussed are the progress of Cybin's CYB003 Phase 3 program, its recent clinical partnerships, and a notable collaboration with Thermo Fisher. Additionally, the conversation will delve into the evolving regulatory landscape for psychedelics, offering valuable insights for stakeholders in the mental health and pharmaceutical sectors.

The fireside chat will also explore Cybin's strategic approach to interventional psychiatry and its alliance with Osmind, highlighting the company's commitment to advancing mental health treatments through innovative psychedelic-based therapeutics. Cybin's mission to revolutionize mental healthcare is supported by a network of world-class partners and internationally recognized scientists, focusing on proprietary drug discovery platforms and novel formulation approaches. The company is currently developing CYB003, a deuterated psilocybin analog for major depressive disorder, and CYB004, a deuterated DMT molecule for generalized anxiety disorder, among other investigational compounds.

This discussion is particularly significant for investors, healthcare professionals, and patients alike, as it underscores the potential of psychedelic-based therapies to address the large unmet need in mental health treatment. The event represents an opportunity to gain deeper understanding of Cybin's contributions to the field and the challenges and opportunities within the regulatory environment. For those interested in learning more about Cybin's initiatives, further information is available at https://www.Cybin.com.